↓ Skip to main content

Dove Medical Press

Article Metrics

Role of biologics in intractable urticaria

Overview of attention for article published in Biologics: Targets & Therapy, January 2015
Altmetric Badge

About this Attention Score

  • Among the highest-scoring outputs from this source (#45 of 133)
  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
82 Mendeley
Title
Role of biologics in intractable urticaria
Published in
Biologics: Targets & Therapy, January 2015
DOI 10.2147/btt.s63839
Pubmed ID
Authors

Cooke, Andrew, Bulkhi, Adeeb, Casale, Thomas B

Abstract

Chronic urticaria (CU) is a common condition faced by many clinicians. CU has been estimated to affect approximately 0.5%-1% of the population, with nearly 20% of sufferers remaining symptomatic 20 years after onset. Antihistamines are the first-line therapy for CU. Unfortunately, nearly half of these patients will fail this first-line therapy and require other medication, including immune response modifiers or biologics. Recent advances in our understanding of urticarial disorders have led to more targeted therapeutic options for CU and other urticarial diseases. The specific biologic agents most investigated for antihistamine-refractory CU are omalizumab, rituximab, and intravenous immunoglobulin (IVIG). Of these, the anti-IgE monoclonal antibody omalizumab is the best studied, and has recently been approved for the management of CU. Other agents, such as interleukin-1 inhibitors, have proved beneficial for Schnitzler syndrome and cryopyrin-associated periodic syndromes (CAPS), diseases associated with urticaria. This review summarizes the relevant data regarding the efficacy of biologics in antihistamine-refractory CU.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 82 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Canada 1 1%
Unknown 81 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 14 17%
Student > Master 12 15%
Student > Bachelor 10 12%
Student > Ph. D. Student 9 11%
Student > Doctoral Student 6 7%
Other 18 22%
Unknown 13 16%
Readers by discipline Count As %
Medicine and Dentistry 35 43%
Nursing and Health Professions 6 7%
Biochemistry, Genetics and Molecular Biology 4 5%
Pharmacology, Toxicology and Pharmaceutical Science 3 4%
Agricultural and Biological Sciences 2 2%
Other 12 15%
Unknown 20 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 November 2015.
All research outputs
#2,712,885
of 6,564,711 outputs
Outputs from Biologics: Targets & Therapy
#45
of 133 outputs
Outputs of similar age
#83,904
of 173,135 outputs
Outputs of similar age from Biologics: Targets & Therapy
#3
of 3 outputs
Altmetric has tracked 6,564,711 research outputs across all sources so far. This one has received more attention than most of these and is in the 56th percentile.
So far Altmetric has tracked 133 research outputs from this source. They receive a mean Attention Score of 2.2. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 173,135 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.